Specific Biologics Raises US$35 Million in Series A Financing
Specific Biologics announced an oversubscribed US$35 million Series A financing to advance its gene-editing therapy for ALS.
Related stories
Coface New Business Hits Record €105M for 9M-26
Coface said new business reached a record €105 million for 9M-26.
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC
Q·CAPITAL Q3 Comprehensive Loss Widens to CHF 842,361
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC
Q·CAPITAL’s Q3 2026 Loss Widens
Q·CAPITAL reported a wider loss in the third quarter of 2026 than a year earlier.
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC
Coface Reports Net Income, Including Third-Quarter Results
Coface reported an annualized RoATE.
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC
Grifols Reports Q3 Revenue of €538 Million
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC
Motilal Oswal Recommends Buying Indostar Capital Finance, Sets Rs 240 Target
Motilal Oswal’s report says Indostar Capital Finance’s 2QFY27 PAT was INR132m, versus INR115m in 1QFY27. NII grew 34% year over year to INR2b; other income was INR407m and opex ros
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC